13 research outputs found
Organometallic Cages as Vehicles for Intracellular Release of Photosensitizers
Water-soluble metalla-cages were used to deliver hydrophobic porphin molecules to cancer cells. After internalization, the photosensitizer was photoactivated, significantly increasing the cytotoxicity in cells. During the transport, the photosensitizer remains nonreactive to light, offering a new strategy to tackle overall photosensitization, a limitation often encountered in photodynamic therapy
Direct Guanidinylation of Aryl and Heteroaryl Halides via Copper-Catalyzed Cross-Coupling Reaction
A modified Ullmann reaction using <i>p</i>-methoxybenzyl
(PMB) guanidine as guanidinylation agent yielded various aryl and
heteroaryl guanidines in good yields
Aminoguanidine Hydrazone Derivatives as Nonpeptide NPFF1 Receptor Antagonists Reverse Opioid Induced Hyperalgesia
Neuropeptide
FF receptors (NPFF1R and NPFF2R) and their endogenous ligand neuropeptide
FF have been shown previously to display antiopioid properties and
to play a critical role in the adverse effects associated with chronic
administrations of opiates including the development of opioid-induced
hyperalgesia and analgesic tolerance. In this work, we sought to identify
novel NPFF receptors ligands by focusing our interest in a series
of heterocycles as rigidified nonpeptide NPFF receptor ligands, starting
from already described aminoguanidine hydrazones (AGHs). Binding experiments
and functional assays highlighted AGH <b>1n</b> and its rigidified
analogue 2-amino-dihydropyrimidine <b>22e</b> for in vivo experiments.
As shown earlier with the prototypical dipeptide antagonist RF9, both <b>1n</b> and <b>22e</b> reduced significantly the long lasting
fentanyl-induced hyperalgesia in rodents. Altogether these data indicate
that AGH rigidification maintains nanomolar affinities for both NPFF
receptors, while improving antagonist character toward NPFF1R
In Situ Generated Fluorinated Iminium Salts for Difluoromethylation and Difluoroacetylation
The use of TFEDMA, a fluoroalkyl
amino reagent, for the difluoromethylation
and difluoroacylation of arenes, heteroarenes, and CāH acidic
compounds is reported. This approach allows for an efficient access
to difluoromethylated products of high added value in good to excellent
yields and with scale-up possibilities
Heteroarylguanidines as Allosteric Modulators of ASIC1a and ASIC3 Channels
Acid-sensing ion
channels (ASICs) are neuronal Na<sup>+</sup>-selective
ion channels that open in response to extracellular acidification.
They are involved in pain, fear, learning, and neurodegeneration after
ischemic stroke. 2-Guanidine-4-methylquinazoline (GMQ) was recently
discovered as the first nonproton activator of ASIC3. GMQ is of interest
as a gating modifier and pore blocker of ASICs. It has however a low
potency, and exerts opposite effects on ASIC1a and ASIC3. To further
explore the molecular mechanisms of GMQ action, we have used the guanidinium
moiety of GMQ as a scaffold and tested the effects of different GMQ
derivatives on the ASIC pH dependence and maximal current. We report
that GMQ derivatives containing quinazoline and quinoline induced,
as GMQ, an alkaline shift of the pH dependence of activation in ASIC3
and an acidic shift in ASIC1a. Another group of 2-guanidinopyridines
shifted the pH dependence of both ASIC1a and ASIC3 to more acidic
values. Several compounds induced an alkaline shift of the pH dependence
of ASIC1a/2a and ASIC2a/3 heteromers. Compared to GMQ, guanidinopyridines
showed a 20-fold decrease in the IC<sub>50</sub> for ASIC1a and ASIC3
current inhibition at pH 5. Strikingly, 2-guanidino-quinolines and
-pyridines showed a concentration-dependent biphasic effect that resulted
at higher concentrations in ASIC1a and ASIC3 inhibition (IC<sub>50</sub> > 100 Ī¼M), while causing at lower concentration a potentiation
of ASIC1a, but not ASIC3 currents (EC<sub>50</sub> ā 10 Ī¼M).
In conclusion, we describe a new family of small molecules as ASIC
ligands and identify an ASIC subtype-specific potentiation by a subgroup
of these compounds
Development of a Peptidomimetic Antagonist of Neuropeptide FF Receptors for the Prevention of Opioid-Induced Hyperalgesia
Through the development of a new
class of unnatural ornithine derivatives
as bioisosteres of arginine, we have designed an orally active peptidomimetic
antagonist of neuropeptide FF receptors (NPFFR). Systemic low-dose
administration of this compound to rats blocked opioid-induced hyperalgesia,
without any apparent side-effects. Interestingly, we also observed
that this compound potentiated opioid-induced analgesia. This unnatural
ornithine derivative provides a novel therapeutic approach for both
improving analgesia and reducing hyperalgesia induced by opioids in
patients being treated for chronic pain
Access to 4āAlkylaminopyridazine Derivatives via Nitrogen-Assisted Regioselective Pd-Catalyzed Reactions
3-Substituted,
6-substituted, and unsymmetrical 3,6-disubstituted
4-alkylaminopyridazines were prepared from a sequence of three chemo-
and regioselective reactions combining amination and palladium-catalyzed
cross-coupling reactions, such as reductive dehalogenation and SuzukiāMiyaura
reactions. Extension of the methodology to Sonogashira reaction yielded
a novel class of 3-substituted pyrrolopyridazines
Fully Regiocontrolled Polyarylation of Pyridine
Starting
from commercially available 2-chloro-3-hydroxypyridine,
a new route leading to the first protypical pentaarylpyridine bearing
five different substituents is reported. This strategy involves a
set of five sequential but fully regiocontrolled SuzukiāMiyaura
reactions and highlights the 2-OBn pyridine protecting group as a
key intermediate. The 2-OBn group played a double role: (i) it allowed
additional bromination at position 5 and (ii) it could afford the
reactive OTf species for the last C-arylation step at the less hindered
2 position of the tetraarylpyridine. The photophysical properties
of the novel compounds are also described. The synthesized pentaarylpyridine
derivative exhibit a large Stokes shift, strong solvatochromism, and
quantum yield values up to 0.47; thus, they constitute promising building
blocks for the design of environment-sensitive probes
StructureāActivity Relationship Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost Ī±2-Adrenergic Receptor Agonistic Activity
Guanabenz
(GA) is an orally active Ī±2-adrenergic agonist
that has been used for many years for the treatment of hypertension.
We recently described that GA is also active against both yeast and
mammalian prions in an Ī±2-adrenergic receptor-independent manner.
These data suggest that this side-activity of GA could be explored
for the treatment of prion-based diseases and other amyloid-based
disorders. In this perspective, the potent antihypertensive activity
of GA happens to be an annoying side-effect that could limit its use.
In order to get rid of GA agonist activity at Ī±2-adrenergic
receptors, we performed a structureāactivity relationship study
around GA based on changes of the chlorine positions on the benzene
moiety and then on the modifications of the guanidine group. Hence,
we identified the two derivatives <b>6</b> and <b>7</b> that still possess a potent antiprion activity but were totally
devoid of any agonist activity at Ī±2-adrenergic receptors. Similarly
to GA, <b>6</b> and <b>7</b> were also able to inhibit
the protein folding activity of the ribosome (PFAR) which has been
suggested to be involved in prion appearance/maintenance. Therefore,
these two GA derivatives are worth being considered as drug candidates